Dr. Evi Mercken is CSO at Rejuvenate Biomed and a member of the management board. As CSO, she provides strategic and scientific leadership across a range of R&D activities, including in-silico tools, cell culture models, C. elegans platforms, and preclinical mouse studies. With nearly 20 years of international experience in the field of aging, Evi brings deep expertise in translational research focused on the molecular mechanisms underlying the aging process. Her work elucidates how interventions—whether dietary, pharmaceutical, or genetic—can extend lifespan and improve healthspan in both model organisms and humans. Throughout her career, she has played a key role in collaborative projects examining factors such as nuclear factor erythroid 2–related factor 2 (Nrf2) in the context of aging, metabolism, and age-related diseases, including cancer. She has been awarded competitive research funding from agencies such as Flanders Innovation and Entrepreneurship (VLAIO) and the Research Foundation – Flanders (FWO). Her broad contributions in the fields of metabolism, degenerative muscle disease, and aging have spearheaded targeted translational efforts to improve the quality of life. Evi worked as a postdoc at the National Institute on Aging, US, and holds a PhD in Life Sciences and a master’s degree in Biological Health Sciences from Maastricht University, Netherlands.